Beijing, China, October 15, 2018—Sinotau Pharmaceutical Group (the Company) announced today that, in accordance with the applicable U.S. laws, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH) granted the Company an exclusive worldwide license for the development and commercialization of a patent estate covering inventions for radionuclide therapy for metastatic castration-resistant prostate cancer.
“With the introduction of this product Sinotau is stepping into a new era of development for therapeutic radionuclides that will reshape the future of the Company,” said Mr. Sam (Xinsheng) Xu, the Chief Executive Officer and Chairman of Sinotau board of directors. “We are grateful to the brilliant inventors Drs. Xiaoyuan Chen and Orit Jacobson Weiss of NIBIB, for developing this glorious molecule, with the potential to benefit patients all over the world. We also highly appreciate the NHLBI Office of Technology Transfer and Development for negotiating and granting a license to Sinotau”.
About the Company:
Sinotau Pharmaceutical Group (Sinotau) is headquartered in Beijing, China. The company was launched in 2004 with the initial goal to develop, manufacture and commercialize imported and local generic medicines in China. Since 2014, the company has extended its efforts into radiopharmaceutical development and commercialization in China, and through both licensing and in-house development the Company has implemented an imaging pipeline in the fields of oncology, neurodegenerative diseases and cardiovascular diseases, along with an oncology therapy (theranostics) pipeline. The company has approximately 260 full-time employees, with a subsidiary in USA (Sinotau USA).
For more information, please visit: www.sinotau.com or
Sinotau Contact: Sam Xu, President and CEO, at email@example.com
Licensing Contact: Michael Shimilovich, Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development, NIH. Esq, CLP; 301-435-5019; firstname.lastname@example.org